Tag: Cardiosence

Cardiosense Presents New Analysis of the SEISMIC-HF I Study Validating its AI Algorithm for Noninvasive PCWP Assessment at the American Heart Association’s 2025 Scientific Sessions

Coronary/Structural Heart by 0 comments

CHICAGO–(BUSINESS WIRE)–Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, today announced a secondary analysis from the SEISMIC-HF I study on the performance of an AI algorithm for noninvasive congestion assessment at the point of care. The new analysis will be presented by Marat Fudim, MD, Associate […]

Continue Reading →

Cardiosense receives FDA Breakthrough Device designation for algorithm to identify patients at risk of decompensated heart failure

Coronary/Structural Heart Regulatory by 0 comments

CHICAGO, Feb. 15, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company building a physiological waveform AI platform to manage cardiac disease, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device status for its novel algorithm to identify patients at risk of decompensated heart failure. The algorithm analyzes […]

Continue Reading →